AOL Money & Finance

Options update 12-20-07: Genitope calls spike ahead of MyVax results

More

Genitope (NASDAQ: GTOP) plans to issue a press release after 4:00 pm EST today that will discuss the initial results of its pivotal Phase 3 clinical trial examining GTOP's MyVax (personalized immunotherapy vaccine for follicular non-Hodgkin's lymphoma). GTOP is recently down $1.24 to $3.00. GTOP call option volume of 46,827 contracts compares to put volume of 6,584 contracts according to Track Data, suggesting large price risk.

Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Symbol Lookup
IndexesChangePrice
DJIA+30.6910,464.40
NASDAQ+6.872,176.05
S&P 500+4.981,110.63

Last updated: November 26, 2009: 12:23 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines